Phreesia Securities Fraud Class Actions
Analysis based on 303 articles · First reported Apr 14, 2026 · Last updated Jul 05, 2026
The multiple class action lawsuits against Phreesia for alleged securities fraud have negatively impacted investor confidence, leading to a significant drop in Phreesia's stock price. The ongoing legal proceedings and the allegations of misleading statements regarding revenue projections and weakened pharmaceutical marketing commitments are likely to cause continued volatility and uncertainty for Phreesia's stock.
Multiple law firms, including The Schall Law Firm, Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Glancy Prongay & Murray, DJS Law Group, Rosen Law Firm, The Law Offices of Frank R. Cruz, and Faruqi & Faruqi, have announced or filed class action lawsuits against Phreesia, Inc. The lawsuits allege that Phreesia made false and misleading statements to investors between May 8, 2025, and March 30, 2026. Specifically, the complaints claim that Phreesia misrepresented its long-term growth outlook and confidence in fiscal year 2027 revenue projections, while downplaying risks from slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment. Following Phreesia's announcement of significantly reduced revenue growth projections on March 30, 2026, its stock price fell by 26.56%. Investors who purchased Phreesia securities during the specified period are being encouraged to join these lawsuits, with a lead plaintiff deadline of July 13, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard